Contineum Therapeutics, Inc. Class A Common Stock (CTNM) — Free Cash Flow Generation Index
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has a Free Cash Flow Generation Index of 1.00x as of June 2023. Free cash flow of $40.64 Million represents 1% of operating cash flow ($40.67 Million). Explore Contineum Therapeutics, Inc. Class A Com capital spending ratio to see what proportion of operating cash flow is directed to capital expenditures.
FCF Generation Index
Free Cash Flow
Operating Cash Flow
Capital Expenditures
Contineum Therapeutics, Inc. Class A Common Stock Free Cash Flow Generation Index (2023–2023)
Historical FCF Generation Index trend for Contineum Therapeutics, Inc. Class A Common Stock across 1 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Contineum Therapeutics, Inc. Class A Com.
Annual Free Cash Flow Generation for Contineum Therapeutics, Inc. Class A Common Stock (2023–2023)
Year-by-year Free Cash Flow Generation Index for Contineum Therapeutics, Inc. Class A Common Stock. Check CTNM cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
| Year | FCG Index | Free Cash Flow (USD) | Operating CF | Capital Expenditures | YoY Change |
|---|---|---|---|---|---|
| 2023 | 0.98x | $18.93 Million | $19.35 Million | $414.00K | — |